Clinical Trials Browser

Phase 2 × naxitamab × Sarcoma × Clear all

NCT02502786 2025-10-07

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Phase 2 Active not recruiting

Osteosarcoma

NCT05968768 2025-04-10

To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)

Phase 2 Recruiting

Sarcoma, Ewing

NCT06438614 2024-08-29

NICE

Phase 2 Completed

Neuroblastoma, Sarcoma